Sana’s HIP Technology Brings Us One Step Closer to a Type 1 Diabetes Cure

Sana Biotechnology has achieved a breakthrough: a person with type 1 diabetes is now producing insulin after receiving specially engineered islet cells—without the need for anti-rejection drugs.

In type 1 diabetes, the immune system destroys insulin-producing islet cells (islets). Transplanted islets face the same attack, requiring anti-rejection drugs with serious side effects. 

Sana’s breakthrough offers a safer, drug-free way to restore insulin production.

Key Takeaways from the HIP Technology Study

Key Findings from this first-in-human HIP technology study:

• Islet Cell Function and Persistence: Islets from a deceased donor were modified with the HIP technology, then placed into the clinical trial participant, who was then able to produce insulin.
  • After four weeks, tests showed an increase in C-peptide, a marker that confirms the beta cells are alive and producing insulin. This was achieved without immune-suppressing drugs and with no safety concerns.
• Immune Evasion: The HIP-modified islets were designed to hide from the immune system, preventing attacks by the body and rejection of the transplanted cells.
  • This means the immune system did not attack the transplanted cells.
• MRI Evidence of Graft Survival: MRI scans showed the new cells were still alive and working well—even 28 days after being put in.
• Safe so Far: After 4 weeks, the study reported no safety concerns. With the study ongoing, they will continue to monitor patient safety.

What Does the HIP Technology Study Mean for People with Type 1 Diabetes?

• No Anti-Rejection Drugs Needed: A key highlight of this study is that the transplanted cells can function without the need for anti-rejection medication.
  • Anti-rejection drugs have been needed in every other islet-transplant study so far, which can lead to other health issues.
• Potential for a Cure: These results bring us closer to a possible curative treatment for type 1 diabetes. 

What’s Next?

• Sana Biotechnology will continue evaluating the safety, persistence, and function of the transplanted islets. 
• This development is a significant step toward transforming type 1 diabetes treatment and potentially offering patients a life-changing solution.